Iovance Biotherapeutics (NASDAQ:IOVA) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) from a sell rating to a hold rating in a report published on Saturday morning.

A number of other analysts have also recently weighed in on the stock. Barclays upped their target price on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research note on Wednesday, February 25th. The Goldman Sachs Group restated a “sell” rating and set a $2.00 target price on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Finally, Chardan Capital decreased their price target on Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.63.

Get Our Latest Report on IOVA

Iovance Biotherapeutics Trading Down 1.8%

IOVA opened at $3.79 on Friday. The stock’s 50 day simple moving average is $2.74 and its 200-day simple moving average is $2.44. The stock has a market cap of $1.56 billion, a PE ratio of -3.38 and a beta of 0.68. Iovance Biotherapeutics has a 1 year low of $1.64 and a 1 year high of $4.57.

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.04. The firm had revenue of $86.77 million during the quarter, compared to analysts’ expectations of $81.61 million. Iovance Biotherapeutics had a negative return on equity of 54.54% and a negative net margin of 148.41%. Equities analysts forecast that Iovance Biotherapeutics will post -1.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several institutional investors have recently bought and sold shares of the business. Xponance LLC grew its holdings in shares of Iovance Biotherapeutics by 19.4% during the fourth quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 3,950 shares during the last quarter. Raymond James Financial Inc. raised its stake in shares of Iovance Biotherapeutics by 1.4% in the second quarter. Raymond James Financial Inc. now owns 324,098 shares of the biotechnology company’s stock worth $557,000 after acquiring an additional 4,618 shares during the last quarter. R Squared Ltd lifted its position in shares of Iovance Biotherapeutics by 41.4% during the third quarter. R Squared Ltd now owns 16,043 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 4,700 shares in the last quarter. Orion Investment Co grew its stake in shares of Iovance Biotherapeutics by 0.3% during the fourth quarter. Orion Investment Co now owns 1,856,934 shares of the biotechnology company’s stock valued at $5,069,000 after purchasing an additional 5,150 shares during the last quarter. Finally, Flputnam Investment Management Co. grew its stake in shares of Iovance Biotherapeutics by 35.4% during the third quarter. Flputnam Investment Management Co. now owns 20,289 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,300 shares during the last quarter. Institutional investors own 77.03% of the company’s stock.

About Iovance Biotherapeutics

(Get Free Report)

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

See Also